Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas W. Dubensky Jr."'
Autor:
Emily Curran, Xiufen Chen, Leticia Corrales, Douglas E. Kline, Thomas W. Dubensky Jr., Priyanka Duttagupta, Marcin Kortylewski, Justin Kline
Publikováno v:
Cell Reports, Vol 15, Iss 11, Pp 2357-2366 (2016)
Type I interferon (IFN), essential for spontaneous T cell priming against solid tumors, is generated through recognition of tumor DNA by STING. Interestingly, we observe that type I IFN is not elicited in animals with disseminated acute myeloid leuke
Externí odkaz:
https://doaj.org/article/324bdbe85b02424f86577727b292b89d
Autor:
Leticia Corrales, Laura Hix Glickman, Sarah M. McWhirter, David B. Kanne, Kelsey E. Sivick, George E. Katibah, Seng-Ryong Woo, Edward Lemmens, Tamara Banda, Justin J. Leong, Ken Metchette, Thomas W. Dubensky Jr., Thomas F. Gajewski
Publikováno v:
Cell Reports, Vol 11, Iss 7, Pp 1018-1030 (2015)
Spontaneous tumor-initiated T cell priming is dependent on IFN-β production by tumor-resident dendritic cells. On the basis of recent observations indicating that IFN-β expression was dependent upon activation of the host STING pathway, we hypothes
Externí odkaz:
https://doaj.org/article/09b15c62c7fe4563b675d2d57fcdb686
Autor:
Erik Van Dis, Kimberly M. Sogi, Chris S. Rae, Kelsey E. Sivick, Natalie H. Surh, Meredith L. Leong, David B. Kanne, Ken Metchette, Justin J. Leong, Jacob R. Bruml, Vivian Chen, Kartoosh Heydari, Nathalie Cadieux, Tom Evans, Sarah M. McWhirter, Thomas W. Dubensky, Jr., Daniel A. Portnoy, Sarah A. Stanley
Publikováno v:
Cell Reports, Vol 23, Iss 5, Pp 1435-1447 (2018)
Summary: There are a limited number of adjuvants that elicit effective cell-based immunity required for protection against intracellular bacterial pathogens. Here, we report that STING-activating cyclic dinucleotides (CDNs) formulated in a protein su
Externí odkaz:
https://doaj.org/article/5af82e8c90b24ca6bea46b4f64e9ab0e
Autor:
Kelsey E. Sivick, Anthony L. Desbien, Laura Hix Glickman, Gabrielle L. Reiner, Leticia Corrales, Natalie H. Surh, Thomas E. Hudson, Uyen T. Vu, Brian J. Francica, Tamara Banda, George E. Katibah, David B. Kanne, Justin J. Leong, Ken Metchette, Jacob R. Bruml, Chudi O. Ndubaku, Jeffrey M. McKenna, Yan Feng, Lianxing Zheng, Steven L. Bender, Charles Y. Cho, Meredith L. Leong, Andrea van Elsas, Thomas W. Dubensky, Jr., Sarah M. McWhirter
Publikováno v:
Cell Reports, Vol 25, Iss 11, Pp 3074-3085.e5 (2018)
Summary: Intratumoral (IT) STING activation results in tumor regression in preclinical models, yet factors dictating the balance between innate and adaptive anti-tumor immunity are unclear. Here, clinical candidate STING agonist ADU-S100 (S100) is us
Externí odkaz:
https://doaj.org/article/6640eed869a2425eb7c9442fb0d88d76